The agency previously approved Tagrisso to treat patients whose lung cancer worsened after treatment with a different drug or those who developed a secondary genetic mutation, according to Reuters.
Under the new approval, patients whose tumors have an epidermal growth factor receptor mutation may take Tagrisso as an initial treatment. Clinicians identify the mutation via an FDA-approved detection test.
More articles on supply chain:
CVS Health elevates Kevin Hourican to president of CVS Pharmacy: 4 things to know
Coastal Meds recalls all drug products marketed as sterile
HSCA: 4 cybersecurity considerations to address emerging supply chain threats
